The United States cannabis sector is standing on the precipice of a monumental shift. For years, multi-state operators (MSOs) have been relegated to the Canadian Securities Exchange (CSE) and over-the-counter (OTC) markets, largely ignored by major institutional investors due to federal prohibition. However, the tides are turning rapidly. Trulieve Cannabis Corp., currently trading as TCNNF on the OTCQX and TRUL on the CSE, has just announced a watershed moment for the industry: the approval to uplist its subordinate voting shares to the New York Stock Exchange (NYSE).

Expected to begin trading under the ticker symbol “TRLV” on June 10, 2026, Trulieve will become the first U.S. cannabis company to list on a major American exchange. This move not only validates Trulieve’s strategic restructuring but also signals a profound regulatory thaw that could unlock billions in institutional capital for the broader sector.

The Catalyst: Schedule III and Corporate Restructuring

The foundation for this uplisting was laid in April 2026, when Acting Attorney General Todd Blanche reclassified medical marijuana to Schedule III under the Controlled Substances Act, executing a directive signed by President Trump in December 2025. This reclassification created a pathway for state-licensed medical marijuana businesses to register with the Drug Enforcement Administration (DEA), fundamentally altering the legal risk profile of these operations.

Capitalizing on this regulatory shift, Trulieve executed a masterclass in corporate restructuring. The company deconsolidated its operations in states that serve both medical and adult-use customers, isolating its medical-only business. Today, Trulieve’s consolidated operations consist exclusively of state-licensed medical marijuana facilities, including 206 dispensaries and 3.5 million square feet of DEA-registered production capacity across states like Florida, Georgia, Pennsylvania, and West Virginia. This surgical pivot removed the compliance hurdles that have historically barred plant-touching cannabis companies from the NYSE and Nasdaq.

Financial Resilience Amidst Industry Headwinds

Trulieve’s fundamental financial performance provides a strong backbone for its market debut. In the first quarter of 2026, the company reported $287 million in revenue, with a robust gross margin of 59 percent. While revenue saw a slight year-over-year dip, the company’s profitability metrics are striking. Trulieve posted a positive net income of $2.4 million—a significant turnaround from a $32.9 million loss in the same quarter the previous year.

Furthermore, the company generated an adjusted EBITDA of $100 million, representing a 35 percent margin, and produced $56 million in operating cash flow. With $353 million in cash on the balance sheet at the end of Q1, Trulieve is exceptionally well-capitalized to pursue expansion, particularly in high-growth markets like Georgia and Texas. The elimination of the punitive Section 280E tax burden, a direct result of Schedule III reclassification, will further enhance free cash flow generation across the sector.

Sector Implications and Peer Analysis

Trulieve’s successful navigation of the NYSE listing requirements provides a blueprint for other leading MSOs. As institutional investors—many of whom are restricted by mandate from trading OTC stocks—gain access to TRLV, we anticipate a significant liquidity event that could drive valuation multiples closer to traditional consumer packaged goods and pharmaceutical companies.

This rising tide will likely lift other well-positioned operators. Companies like Green Thumb Industries and Curaleaf are closely watching this development. Green Thumb Industries (GTBIF), with its consistent history of operating profitability and strong balance sheet, is a prime candidate to follow Trulieve’s lead. Curaleaf (CURLF), despite recent margin pressures, maintains a massive national footprint that will benefit immensely from broader institutional access.

Verano Holdings (VRNO) is also making aggressive moves, recently announcing a 1-for-5 reverse stock split effective June 11, 2026, explicitly to meet exchange listing price requirements following its redomestication to the United States. Meanwhile, Cresco Labs (CRLBF) continues to battle price compression but remains a key player in the wholesale market.

Even Canadian operators like Tilray Brands (TLRY), which already trade on major U.S. exchanges but have been hampered by their inability to operate plant-touching businesses in the U.S., may see renewed interest as the global cannabis narrative improves. Furthermore, the AdvisorShares Pure US Cannabis ETF (MSOS) stands to benefit as its underlying holdings potentially migrate to major exchanges, improving the fund’s liquidity and appeal.

Equities Orbis Ratings and Price Targets

Based on the shifting regulatory landscape, fundamental financial performance, and the massive liquidity catalyst presented by the NYSE uplisting, Equities Orbis issues the following ratings and 12-month price targets for the companies discussed:

Company	Ticker	Rating	Current Price	12-Mo Target	Rationale
Trulieve Cannabis	TCNNF / TRLV	BUY	$9.82	$18.00	First-mover advantage on NYSE, strong cash flow, elimination of 280E tax burden. Institutional liquidity premium drives multiple expansion.
Green Thumb Industries	GTBIF	BUY	$8.14	$14.50	Consistent profitability and disciplined capital allocation. Prime candidate for future uplisting.
Curaleaf Holdings	CURLF	HOLD	$3.49	$4.50	Massive scale, but requires operational optimization to improve margins before warranting a Buy.
Verano Holdings	VRNO	BUY	$1.53	$3.50	Strategic reverse split and U.S. redomestication signal clear intent for uplisting. Deep value play.
Cresco Labs	CRLBF	HOLD	$0.91	$1.20	Strong wholesale business, but ongoing margin compression and earnings misses suggest caution.
Tilray Brands	TLRY	SELL	$5.19	$4.00	U.S. MSOs gaining major exchange access diminishes Tilray’s unique value proposition as a Nasdaq-listed cannabis proxy.
AdvisorShares US Cannabis ETF	MSOS	BUY	$5.14	$8.50	Excellent vehicle for broad exposure as the sector transitions to major exchanges and benefits from Schedule III tax relief.

Disclaimer: The current price estimates are based on recent OTC market data leading up to the June 2026 uplisting announcements. Market volatility in the cannabis sector is high. This analysis is for informational purposes only and does not constitute investment advice.

Conclusion

The uplisting of Trulieve to the New York Stock Exchange is not merely a corporate milestone; it is the starting gun for the financial normalization of the U.S. cannabis industry. By successfully navigating the complex intersection of federal rescheduling and exchange compliance, Trulieve has unlocked a new era of institutional investment. Investors who position themselves ahead of this liquidity wave stand to benefit as the green rush finally arrives on Wall Street.